Across TCGA pan-cancer cohorts, KIF18B mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated KIF18B data layer compared with 27 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher KIF18B mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated KIF18B expression acts as an unfavorable survival marker, although some lineages such as LSCC and LUAD show a favorable association.

PDAC, LSCC, and LUAD are the cancer types where KIF18B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Quartile	All	0.358	0.991	.001	37	view →
LSCC	OS	Median	All	0.981	0.696	.012	7	view →
LUAD	DFS	Median	II,III,IV	0.797	0.207	.017	3	view →
HNSC	DFS	Tertile	II,III,IV	1.000	0.874	.029	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: KIF18B tumor-vs-normal RNA expression · all KIF18B data types